ライフサイエンスコーパス: lymphoproliferative

1 was inflammatory, followed by structural and lymphoproliferative.

2 Lymphoproliferative and cytokine responses induced with

3 H1N1-specific T-cell responses in lymphoproliferative and IFN-gamma assays were detectable

4 e lacking NFkappaB1 (Nfkappab1(-/-)) develop lymphoproliferative and multiorgan autoimmune disease at

5 e of MGUS in blood relatives of persons with lymphoproliferative and plasma cell proliferative disord

6 l-mediated immune responses as assessed by a lymphoproliferative assay.

7 tectable in survivors' peripheral blood, and lymphoproliferative assays were negative in the three fa

8 A complex resulted in a severe, multi-organ, lymphoproliferative autoimmune disorder.

9 sseminated "mature phenotype" lymphoma and a lymphoproliferative autoimmune syndrome in mice.

10 ically in T cells do not develop spontaneous lymphoproliferative autoimmunity, Smad2-deficient T cell

11 etained T-cell epitopes, as evident from its lymphoproliferative capacity but down-regulated pro-alle

12 I, 1.03-3.10; P = 0.038) and post-transplant lymphoproliferative disease (adjusted HR, 2.72; 95% CI,

13 Dianzani autoimmune lymphoproliferative disease (DALD) has a similar phenoty

14 plantation recipients with biopsy-proven EBV-lymphoproliferative disease (EBV-LPD).

15 te activity can lead to life-threatening EBV lymphoproliferative disease (EBV-PTLD).

16 ymorphic extranodal or (3) polymorphic nodal lymphoproliferative disease (LPD); and (4) diffuse large

17 city (p = 0.014) and previous posttransplant lymphoproliferative disease (PTLD) diagnosis (p = 0.006)

18 the incidence and hazard for posttransplant lymphoproliferative disease (PTLD) in a study of 3170 pe

19 Posttransplantation lymphoproliferative disease (PTLD) is an often Epstein-B

20 Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remains problematic.

21 Optimal management of posttransplant lymphoproliferative disease (PTLD) remains to be defined

22 irus (EBV) is associated with posttransplant lymphoproliferative disease (PTLD), and EBV load measure

23 ding Burkitt's lymphoma (BL), posttransplant lymphoproliferative disease (PTLD), nasopharyngeal carci

24 central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD).

25 ant recipients are at risk of posttransplant lymphoproliferative disease (PTLD).

26 infections and trigger post-transplantation lymphoproliferative disease (PTLD).

27 One of the manifestations of X-linked lymphoproliferative disease (XLP) is progressive agammag

28 s with the primary immunodeficiency X-linked lymphoproliferative disease (XLP), which is caused by mu

29 T cells from patients with X-linked lymphoproliferative disease (XLP), who lack functional S

30 ls from SAP-deficient patients with X-linked lymphoproliferative disease (XLP).

31 X-linked lymphoproliferative disease (XLP1) arises from mutations

32 ergistic signalling is defective in X-linked lymphoproliferative disease (XLP1) NK cells entailing 2B

33 X-linked lymphoproliferative disease 1 (XLP1), due to mutations i

34 e causal gene responsible for XLP2 (X-linked lymphoproliferative Disease 2).

35 y, and EBV-related morbidity (posttransplant lymphoproliferative disease [PTLD] or symptomatic EBV in

36 is a complex retrovirus associated with the lymphoproliferative disease adult T-cell leukemia/lympho

37 ontaneously mounting a severe autoaggressive lymphoproliferative disease and can modulate immune resp

38 onset of a variety of pathologies, including lymphoproliferative disease and cancers.

39 ase but not in EBV-associated posttransplant lymphoproliferative disease and Hodgkin disease.

40 mal in 14 of 16 patients (88%) with X-linked lymphoproliferative disease and in 8 of 14 patients (57%

41 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disease and melanoma.

42 These mice develop a lymphoproliferative disease and occasional transformatio

43 ometimes fatal syndromes, including X-linked lymphoproliferative disease and severe cases of common v

44 ponse rates in patients with post-transplant lymphoproliferative disease as well as EBV-positive lymp

45 cally decreased risks of posttransplantation lymphoproliferative disease but is followed by a prolong

46 g Pten in Treg cells developed an autoimmune-lymphoproliferative disease characterized by excessive T

47 n cancer, Kaposi sarcoma, and posttransplant lymphoproliferative disease have standardized incidence

48 human malignancies including posttransplant lymphoproliferative disease in immunosuppressed patients

49 cell therapy for EBV-driven post-transplant lymphoproliferative disease is stimulating efforts to ta

50 Individuals with X-linked lymphoproliferative disease lack invariant natural kille

51 pment; however, they rapidly develop a fatal lymphoproliferative disease marked by the uncontrolled e

52 This acute and lethal lymphoproliferative disease occurs after a prolonged asy

53 Marek's disease (MD) is a lymphoproliferative disease of chickens caused by the on

54 anular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disease of mature T and natural kill

55 ces malignant catarrhal fever (MCF), a fatal lymphoproliferative disease of ruminants, including catt

56 duced in T cells from patients with X-linked lymphoproliferative disease or normal T cells transfecte

57 Furthermore, in X-linked lymphoproliferative disease patients, SAP deficiency red

58 eficiency with a loss of Ripk3 gives rise to lymphoproliferative disease reminiscent of lpr or gld mi

59 We analyzed the virological and lymphoproliferative disease response (LDR) of 46 patient

60 ribed patients with immune dysregulation and lymphoproliferative disease resulting from 2 different g

61 entiviruses cause an incurable, progressive, lymphoproliferative disease that affects millions of ani

62 granular lymphocytic leukaemia (T-LGL) is a lymphoproliferative disease that presents with immune-me

63 tive for CAEBV, even in patients with active lymphoproliferative disease that was unresponsive to che

64 unopathology of IM in boys with the X-linked lymphoproliferative disease trait, and as a chronic acti

65 h adult T-cell leukemia (ATL), an aggressive lymphoproliferative disease with a dismal prognosis.

66 ed homeostatic expansion, which manifests as lymphoproliferative disease with autoantibody production

67 nce of approximately 80% (49% splenic B-cell lymphoproliferative disease, 28% lymphoma).

68 y immunogenic tumors such as post-transplant lymphoproliferative disease, although resistance occurre

69 stromal lymphopoietin levels, milder B-cell lymphoproliferative disease, and improved survival in Ms

70 Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disease, but the extent of immune de

71 ases of GI involvement by an indolent T-cell lymphoproliferative disease, including 6 men and 4 women

72 O mice developed lupus-like autoimmunity and lymphoproliferative disease, indicating that ubiquitin l

73 ne function; however, treated mice developed lymphoproliferative disease, likely due to viral-promote

74 cleosis, hemophagocytic lymphohistiocytosis, lymphoproliferative disease, organomegaly, and/or malign

75 aired in T cells from patients with X-linked lymphoproliferative disease, which lack SLAM-associated

76 The boy developed posttransplant lymphoproliferative disease, which resolved after treatm

77 e targeted in T cell therapy of EBV-driven B-lymphoproliferative disease.

78 ferentiation into effector cells and induced lymphoproliferative disease.

79 lar to those found in patients with X-linked lymphoproliferative disease.

80 e of the noncanonical NF-kappaB pathway in B lymphoproliferative disease.

81 om macroglobulinemia is a distinct low-grade lymphoproliferative disease.

82 TNF-family receptor result in autoimmune and lymphoproliferative disease.

83 reated before HSCT because of EBV-associated lymphoproliferative disease.

84 entially fatal EBV-associated posttransplant lymphoproliferative disease.

85 many are at increased risk of virus-driven B-lymphoproliferative disease.

86 onucleosis or its fatal equivalent, X-linked lymphoproliferative disease; (ii) EBV infection in a ran

87 drome/myeloproliferative neoplasm (19%), and lymphoproliferative diseases (30%).

88 Posttransplantation lymphoproliferative diseases (PTLD) are mainly Epstein-B

89 hotropic herpesvirus strongly linked to both lymphoproliferative diseases and Kaposi's sarcoma.

90 lls are frequently observed in several other lymphoproliferative diseases as well.

91 ologically against inflammatory, immune, and lymphoproliferative diseases for more than 50 years.

92 Lymphadenopathy in autoimmune and other lymphoproliferative diseases is in part characterized by

93 V in the pathogenesis of EBV-positive T-cell lymphoproliferative diseases largely unresolved.

94 B-cell-tropic virus associated with various lymphoproliferative diseases of both B-cell and non-B-ce

95 ped hematologic malignancies (posttransplant lymphoproliferative diseases, 18; Hodgkin disease, 2; an

96 erative syndromes, hemophagocytic disorders, lymphoproliferative diseases, and novel differential dia

97 ciated with the development of lymphomas and lymphoproliferative diseases, as well as several other t

98 ced-stage PSC was 18.7%, with posttransplant lymphoproliferative diseases, colorectal cancer, and ren

99 nstrated to promote Treg cell suppression of lymphoproliferative diseases, has an unexpected function

100 esviral infection is closely associated with lymphoproliferative diseases, including B cell lymphomas

101 opment of Kaposi's sarcoma and several other lymphoproliferative diseases, including primary effusion

102 that are associated with the development of lymphoproliferative diseases, lymphomas, as well as othe

103 ciated with Kaposi sarcoma (KS) and 2 B cell lymphoproliferative diseases, namely primary effusion ly

104 in clinical development for treating B-cell lymphoproliferative diseases.

105 lticentric Castleman disease (MCD) and other lymphoproliferative diseases.

106 r the potential development of MCD and other lymphoproliferative diseases.

107 etiologic agent of Kaposi's sarcoma (KS) and lymphoproliferative diseases.

108 etent people, EBV causes several cancers and lymphoproliferative diseases.

109 he role of EBV in the pathogenesis of T-cell lymphoproliferative diseases.

110 can potentially be targeted in autoimmune or lymphoproliferative diseases.

111 ses infectious mononucleosis and can lead to lymphoproliferative diseases.

112 velopment of three major human neoplastic or lymphoproliferative diseases: Kaposi's sarcoma (KS), pri

113 y et al describe cases of an indolent T-cell lymphoproliferative disorder (LPD) of the gastrointestin

114 tein-Barr virus (EBV)-related posttransplant lymphoproliferative disorder (PTLD) after a rituximab-ba

115 tandard in the management of post-transplant lymphoproliferative disorder (PTLD) and identified respo

116 new safety signals and no new posttransplant lymphoproliferative disorder (PTLD) cases after month 18

117 Posttransplant lymphoproliferative disorder (PTLD) continues to be a de

118 guished untreated, EBV(+)posttransplantation lymphoproliferative disorder (PTLD) from EBV(+)PTLD in r

119 the relationship between posttransplantation lymphoproliferative disorder (PTLD) incidence and presen

120 Posttransplant lymphoproliferative disorder (PTLD) is a major complicat

121 Posttransplant lymphoproliferative disorder (PTLD) is a potentially fat

122 Posttransplant lymphoproliferative disorder (PTLD) is a serious complic

123 Posttransplant lymphoproliferative disorder (PTLD) is a well-establishe

124 Posttransplantation lymphoproliferative disorder (PTLD) is a well-recognized

125 Posttransplant lymphoproliferative disorder (PTLD) is an infrequent but

126 Post-transplantation lymphoproliferative disorder (PTLD) is associated with s

127 pressive regimens (ISRs) with posttransplant lymphoproliferative disorder (PTLD) may be related with

128 n-Barr virus (EBV)-associated posttransplant lymphoproliferative disorder (PTLD) remains a major caus

129 scribe a form of plasmacytic post-transplant lymphoproliferative disorder (PTLD) that occurs in pedia

130 n EBV+ B cell lymphomas from post-transplant lymphoproliferative disorder (PTLD) to discover virally

131 Posttransplantation lymphoproliferative disorder (PTLD), a complication of l

132 skin cancer, solid tumor, and posttransplant lymphoproliferative disorder (PTLD).

133 h infectious mononucleosis to posttransplant lymphoproliferative disorder (PTLD).

134 stent with a polymorphic posttransplantation lymphoproliferative disorder (PTLD).

135 subtype of monomorphic B-cell posttransplant lymphoproliferative disorder (PTLD).

136 B-cell lymphoma (DLBCL), and posttransplant lymphoproliferative disorder (PTLD).

137 ith the highest incidence was posttransplant lymphoproliferative disorder (PTLD, 1.58%), followed by

138 al Treatment of CD20-Positive Posttransplant Lymphoproliferative Disorder (PTLD-1) trial established

139 Interestingly, however, a massive lymphoproliferative disorder and cellular transformation

140 r, the mechanisms by which HCV causes B-cell lymphoproliferative disorder are still unclear.

141 entric Castleman disease (HIV-MCD) is a rare lymphoproliferative disorder caused by infection with hu

142 Like Wp-BL cells, posttransplant lymphoproliferative disorder cells depended on the virus

143 Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by markedly e

144 arge granular lymphocytic leukemia is a rare lymphoproliferative disorder characterized by the expans

145 Multicentric Castleman's disease is a rare lymphoproliferative disorder driven by dysregulated prod

146 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c

147 macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined c

148 Postransplant lymphoproliferative disorder is an important concern, oc

149 presents a potential treatment for the CD30+ lymphoproliferative disorder lymphomatoid papulosis (LyP

150 ed multicentric Castleman disease (MCD) is a lymphoproliferative disorder most commonly observed in H

151 Anemia, neutropenia and posttransplant lymphoproliferative disorder occurred more frequently in

152 HVLL is an EBV-associated lymphoproliferative disorder of alphabeta-, gammadelta-,

153 an Epstein-Barr virus (EBV)-positive T-cell lymphoproliferative disorder of childhood that occurs ma

154 Posttransplant lymphoproliferative disorder remains an important concer

155 rrier function, resulting in a more severe B-lymphoproliferative disorder that persisted into adultho

156 k-old Fas mutant (lpr) mice, before an overt lymphoproliferative disorder was observable.

157 ttransplant malignancies, and posttransplant lymphoproliferative disorder were 3.2 (1.6-5.7), 3.2 (1.

158 nucleotide exchange factor Rasgrp1 develop a lymphoproliferative disorder with features of human syst

159 oup (one CMV; one EBV-related posttransplant lymphoproliferative disorder).

160 expression in cases of human posttransplant lymphoproliferative disorder, a malignant condition asso

161 ive with no single example of posttransplant lymphoproliferative disorder, graft-versus-host disease,

162 lticentric Castleman disease (KSHV-MCD) is a lymphoproliferative disorder, most commonly seen in HIV-

163 In the case of posttransplant lymphoproliferative disorder, the EBV DNA from the donor

164 entric Castleman disease (HIV MCD) is a rare lymphoproliferative disorder, the incidence of which app

165 s, and 99.1% of patients were posttransplant lymphoproliferative disorder-free through 5 years.

166 risks, such as infectious mononucleosis and lymphoproliferative disorder.

167 g a possible explanation for female-specific lymphoproliferative disorder.

168 , a life-threatening, virally induced B-cell lymphoproliferative disorder.

169 LYG) is a rare Epstein-Barr virus-associated lymphoproliferative disorder.

170 There were no cases of lymphoproliferative disorder.

171 xperience higher incidence of posttransplant lymphoproliferative disorder.

172 stleman disease (MCD) is a polyclonal B-cell lymphoproliferative disorder.

173 entric Castleman disease (MCD) as a distinct lymphoproliferative disorder.

174 ble, display fully penetrant female-specific lymphoproliferative disorder.

175 5 x 10(9)/L B-cells and no other signs of a lymphoproliferative disorder.

176 al B-cell, and 1 CR of 3 with posttransplant lymphoproliferative disorder.

177 skin, solid malignancies, and posttransplant lymphoproliferative disorder.

178 lymphoma (SMZL), and 52 with B-cell chronic lymphoproliferative disorders (B-CLPD).

179 we examined 811 consecutive cases of B-cell lymphoproliferative disorders (B-LPDs), and demonstrated

180 ome of patients with CD30+ primary cutaneous lymphoproliferative disorders (CD30CLPD) and early mycos

181 t an exhaustive search for pathogenic DNA in lymphoproliferative disorders (LPD) of the ocular adnexa

182 e syndromes of EBV-associated posttransplant lymphoproliferative disorders (PTLD) and Kaposi's sarcom

183 Posttransplant lymphoproliferative disorders (PTLD) are a common malign

184 iated with increased risk for posttransplant lymphoproliferative disorders (PTLD) in liver transplant

185 We previously reported that posttransplant lymphoproliferative disorders (PTLD) occurred more frequ

186 Posttransplantation lymphoproliferative disorders (PTLD) present a major cau

187 Posttransplant lymphoproliferative disorders (PTLDs) are associated wit

188 Posttransplant lymphoproliferative disorders (PTLDs) are potentially fa

189 EBV(-) posttransplantation lymphoproliferative disorders (PTLDs) are rare compared

190 ut knowledge of their role in posttransplant lymphoproliferative disorders (PTLDs) is limited.

191 mia (WM) cases, and the clustering of B-cell lymphoproliferative disorders among first-degree relativ

192 We screened 418 patients with B-cell lymphoproliferative disorders and described the presence

193 s for familial MGUS and myeloma, the risk of lymphoproliferative disorders and other malignancies amo

194 re was no association between posttransplant lymphoproliferative disorders and pretransplant MGUS.

195 rstanding the viral associations in specific lymphoproliferative disorders and the molecular mechanis

196 T-cell lymphoproliferative disorders are a heterogeneous group

197 t-acting antivirals (DAAs) in HCV-associated lymphoproliferative disorders are scanty.

198 sease describes a group of poorly understood lymphoproliferative disorders driven by proinflammatory

199 Bacteria can induce human lymphomas, whereas lymphoproliferative disorders have been described in pat

200 ogren's syndrome in 22.5% of patients and to lymphoproliferative disorders in 28.7% of patients, and

201 n was also found in EBV/KSHV dually infected lymphoproliferative disorders in humans.

202 fection that often develops into more severe lymphoproliferative disorders in immune-compromised anim

203 ation was associated with the development of lymphoproliferative disorders in mice.

204 ents for CWID and RICD leads to autoimmunune lymphoproliferative disorders in mouse and human.

205 C virus (HCV) is associated with the B-cell lymphoproliferative disorders mixed cryoglobulinemia (MC

206 identify new markers, and to define multiple lymphoproliferative disorders more accurately.

207 Chronic lymphoproliferative disorders of natural killer cells (C

208 h it establishes latency, and can also cause lymphoproliferative disorders of these cells manifesting

209 This case is a reminder that lymphoproliferative disorders often mimic other neurolog

210 lonal clone or development of posttransplant lymphoproliferative disorders or other malignancy.

211 e, proteinuria, c-peptide, viral infections, lymphoproliferative disorders or posttransplant diabetes

212 orders such as systemic lupus erythematosus; lymphoproliferative disorders such as chronic lymphocyti

213 These 2 subjects had B-cell chronic lymphoproliferative disorders that did not fulfill the d

214 nd from polyclonal HHV8-positive plasmacytic lymphoproliferative disorders to bone marrow failure and

215 fections were equally low in both groups (no lymphoproliferative disorders were observed).

216 ting immunoglobulins that occur secondary to lymphoproliferative disorders, chronic viral infections,

217 response to immunotherapy, autoimmunity, and lymphoproliferative disorders, contributing overall to p

218 f the diffuse cystic lung diseases caused by lymphoproliferative disorders, genetic mutations, or abe

219 the development of EBV-associated lymphomas, lymphoproliferative disorders, hemophagocytic lymphohist

220 enic human virus, is associated with several lymphoproliferative disorders, including Burkitt lymphom

221 ought to increase the risk of malignancy and lymphoproliferative disorders, including hemophagocytic

222 which are associated with the development of lymphoproliferative disorders, including lymphomas, reac

223 EBV-infected B cells causes life-threatening lymphoproliferative disorders, including mostly germinal

224 miR-155 acts as an oncogenic miR in B-cell lymphoproliferative disorders, including Waldenstrom mac

225 tasizing neoplasms, polyclonal or monoclonal lymphoproliferative disorders, infections, interstitial

226 or of interleukin-6 that is linked to B-cell lymphoproliferative disorders, is downregulated when eit

227 s (KSHV) is causatively linked to two B cell lymphoproliferative disorders, multicentric Castleman's

228 Among indolent B cell lymphoproliferative disorders, NOTCH2 mutations are rest

229 gent for Kaposi's sarcoma (KS) and two other lymphoproliferative disorders, primary effusion lymphoma

230 EBV is also associated with a variety of lymphoproliferative disorders, typically of B cell origi

231 Hodgkin and Hodgkin lymphomas, as well as in lymphoproliferative disorders, which occur more commonly

232 by its association with a variety of T-cell lymphoproliferative disorders.

233 targeted therapy for CLL and related B-cell lymphoproliferative disorders.

234 omplications, enteropathy, autoimmunity, and lymphoproliferative disorders.

235 is associated with an increased incidence of lymphoproliferative disorders.

236 enia, chronic EBV infection, and EBV-related lymphoproliferative disorders.

237 nctional polarization was examined in T-cell lymphoproliferative disorders.

238 ted with neurological, gastrointestinal, and lymphoproliferative disorders.

239 al differences in the pathogenesis of B-cell lymphoproliferative disorders.

240 ribute to the development of KSHV-associated lymphoproliferative disorders.

241 activation can be operative in these chronic lymphoproliferative disorders.

242 acroglobulinemia, and 57 with B-cell chronic lymphoproliferative disorders.

243 of progression to late-onset posttransplant lymphoproliferative disorders.

244 ved Kaposi sarcoma (KS) and also for certain lymphoproliferative disorders.

245 introduced to reduce risk of posttransplant lymphoproliferative disorders.

246 increases in cardiovascular event risk, and lymphoproliferative disorders.

247 mechanisms underlying HCV-associated B-cell lymphoproliferative disorders.

248 twork of target mRNAs associated with B-cell lymphoproliferative disorders.

249 somal locus 6q14.1, a mutational hot spot in lymphoproliferative disorders.

250 wel disease (IBD), rheumatoid arthritis, and lymphoproliferative disorders.

251 have also been found in patients with other lymphoproliferative disorders.

252 inhibition (HI), microneutralization, ELISA, lymphoproliferative, ELISpot IFN-gamma, and cytokine and

253 SLAM)-associated protein (SAP), the X-linked lymphoproliferative gene product.

254 patients (71%) had concurrent autoimmune or lymphoproliferative illnesses related to immune dysregul

255 ed multicentric Castleman disease (MCD) is a lymphoproliferative inflammatory disorder commonly assoc

256 mice; 3 of 6 of these animals also developed lymphoproliferative lesions after 12 months of infection

257 an antiproliferative effect of SCF(FBXL2) in lymphoproliferative malignancies.

258 CD) is associated with an increased risk for lymphoproliferative malignancy (LPM).

259 leosis and chronic infections that result in lymphoproliferative malignant diseases.

260 ory (n = 51; 53%), structural (n = 20; 21%), lymphoproliferative (n = 19; 20%), and uncommon (n = 7;

261 manifestations and, at a lesser extent, the lymphoproliferative phenotype and prolongs survival in M

262 actor responsible for ERK activation and the lymphoproliferative phenotype in these mice.

263 erogeneous group of primary cutaneous T-cell lymphoproliferative processes, mainly composed of mycosi

264 T cell lymphoproliferative responses and levels of IFN-gamma we

265 (bright) cells and their ability to suppress lymphoproliferative responses at 1 year of age were asso

266 nonuclear cell phytohemagglutinin-stimulated lymphoproliferative responses decreased significantly wi

267 Lymphoproliferative responses in infected human PBMCs we

268 IgG(1) and IgG(2c) type Ab and CD4(+) T cell lymphoproliferative responses.

269 All children (N = 12) with autoimmune lymphoproliferative syndrome (ALPS) achieved a durable c

270 Autoimmune lymphoproliferative syndrome (ALPS) caused by impaired F

271 Autoimmune lymphoproliferative syndrome (ALPS) is a disorder of dis

272 Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder

273 Autoimmune lymphoproliferative syndrome (ALPS) is a human disorder

274 Autoimmune lymphoproliferative syndrome (ALPS) is caused by inactiv

275 Autoimmune lymphoproliferative syndrome (ALPS) is characterized by

276 The autoimmune lymphoproliferative syndrome (ALPS) is characterized by

277 ocument a 20-year experience with autoimmune lymphoproliferative syndrome (ALPS) patients and healthy

278 Autoimmune lymphoproliferative syndrome (ALPS) presents in childhoo

279 Autoimmune lymphoproliferative syndrome (ALPS) represents a failure

280 In autoimmune/lymphoproliferative syndrome (ALPS), defective Fas death

281 human apoptosis disorders is the autoimmune lymphoproliferative syndrome (ALPS), which is caused by

282 ve T cells (DNT) is a hallmark of autoimmune lymphoproliferative syndrome (ALPS).

283 arkable efficacy in children with autoimmune lymphoproliferative syndrome (ALPS).

284 wo distinct inflammatory disorders, X-linked lymphoproliferative syndrome 2 (XLP-2) and very-early-on

285 Fas death receptor or its ligand result in a lymphoproliferative syndrome and exacerbate clinical dis

286 uencing in a patient with NDM and autoimmune lymphoproliferative syndrome and his unrelated, unaffect

287 activated, resulting in the development of a lymphoproliferative syndrome in these mice.

288 X-linked lymphoproliferative syndrome type-2 (XLP-2) is associate

289 CD4(-)CD8(-) T cells, therefore exacerbating lymphoproliferative syndrome, autoimmunity, and organ in

290 X-linked lymphoproliferative syndrome, characterized by fatal res

291 Lymphoproliferative syndrome, production of anti-dsDNA A

292 otential treatments for lupus and autoimmune lymphoproliferative syndrome, without compromising norma

293 ain of STAT5B that presented with autoimmune lymphoproliferative syndrome-like features.

294 systemic lupus erythematosus and autoimmune lymphoproliferative syndrome.

295 toimmunity and lymphomagenesis of autoimmune lymphoproliferative syndrome.

296 ical role of IL-6 in the development of this lymphoproliferative syndrome.

297 l responses to Epstein-Barr virus infection, lymphoproliferative syndromes, and dysgammaglobulinemia.

298 on variable immunodeficiency, and autoimmune lymphoproliferative syndromes, hemophagocytic disorders,

299 Patients with X-linked lymphoproliferative (XLP) disease due to deficiency in t

300 e protein affected in most cases of X-linked lymphoproliferative (XLP) syndrome, a rare genetic disor